188 related articles for article (PubMed ID: 37498408)
1. EZH2 Contributes to Anoikis Resistance and Promotes Epithelial Ovarian Cancer Peritoneal Metastasis by Regulating m6A.
Wang SH; Liu L; Bao KY; Zhang YF; Wang WW; Du S; Jia NE; Suo S; Cai J; Guo JF; Lv G
Curr Med Sci; 2023 Aug; 43(4):794-802. PubMed ID: 37498408
[TBL] [Abstract][Full Text] [Related]
2. Enhancer of zeste homolog 2 promotes the proliferation and invasion of epithelial ovarian cancer cells.
Li H; Cai Q; Godwin AK; Zhang R
Mol Cancer Res; 2010 Dec; 8(12):1610-8. PubMed ID: 21115743
[TBL] [Abstract][Full Text] [Related]
3. LncRNA HOTAIR regulates anoikis-resistance capacity and spheroid formation of ovarian cancer cells by recruiting EZH2 and influencing H3K27 methylation.
Dai ZY; Jin SM; Luo HQ; Leng HL; Fang JD
Neoplasma; 2021 May; 68(3):509-518. PubMed ID: 33502891
[TBL] [Abstract][Full Text] [Related]
4. EZH2 activates CHK1 signaling to promote ovarian cancer chemoresistance by maintaining the properties of cancer stem cells.
Wen Y; Hou Y; Yi X; Sun S; Guo J; He X; Li T; Cai J; Wang Z
Theranostics; 2021; 11(4):1795-1813. PubMed ID: 33408782
[No Abstract] [Full Text] [Related]
5. The H3K9 methyltransferase G9a is a marker of aggressive ovarian cancer that promotes peritoneal metastasis.
Hua KT; Wang MY; Chen MW; Wei LH; Chen CK; Ko CH; Jeng YM; Sung PL; Jan YH; Hsiao M; Kuo ML; Yen ML
Mol Cancer; 2014 Aug; 13():189. PubMed ID: 25115793
[TBL] [Abstract][Full Text] [Related]
6. Protein kinase A-mediated phosphorylation regulates STAT3 activation and oncogenic EZH2 activity.
Özeş AR; Pulliam N; Ertosun MG; Yılmaz Ö; Tang J; Çopuroğlu E; Matei D; Özeş ON; Nephew KP
Oncogene; 2018 Jun; 37(26):3589-3600. PubMed ID: 29576612
[TBL] [Abstract][Full Text] [Related]
7. Overexpression of EZH2 contributes to acquired cisplatin resistance in ovarian cancer cells in vitro and in vivo.
Hu S; Yu L; Li Z; Shen Y; Wang J; Cai J; Xiao L; Wang Z
Cancer Biol Ther; 2010 Oct; 10(8):788-95. PubMed ID: 20686362
[TBL] [Abstract][Full Text] [Related]
8. EZH2-mediated epigenetic silencing of TIMP2 promotes ovarian cancer migration and invasion.
Yi X; Guo J; Guo J; Sun S; Yang P; Wang J; Li Y; Xie L; Cai J; Wang Z
Sci Rep; 2017 Jun; 7(1):3568. PubMed ID: 28620234
[TBL] [Abstract][Full Text] [Related]
9. FBP1 knockdown decreases ovarian cancer formation and cisplatin resistance through EZH2-mediated H3K27me3.
Xiong X; Lai X; Zhang J; Meng Q; Wang P; Qin S; Liu W; Wang Y; Yao Z; Wang D; Li X; Liu Z; Miao H
Biosci Rep; 2022 Sep; 42(9):. PubMed ID: 36000567
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of microRNA let-7b expression by KDM2B promotes cancer progression by targeting EZH2 in ovarian cancer.
Kuang Y; Xu H; Lu F; Meng J; Yi Y; Yang H; Hou H; Wei H; Su S
Cancer Sci; 2021 Jan; 112(1):231-242. PubMed ID: 33091189
[TBL] [Abstract][Full Text] [Related]
11. Essential role for activation of the Polycomb group (PcG) protein chromatin silencing pathway in metastatic prostate cancer.
Berezovska OP; Glinskii AB; Yang Z; Li XM; Hoffman RM; Glinsky GV
Cell Cycle; 2006 Aug; 5(16):1886-901. PubMed ID: 16963837
[TBL] [Abstract][Full Text] [Related]
12. The histone methyltransferase WHSC1 is regulated by EZH2 and is important for ovarian clear cell carcinoma cell proliferation.
Kojima M; Sone K; Oda K; Hamamoto R; Kaneko S; Oki S; Kukita A; Machino H; Honjoh H; Kawata Y; Kashiyama T; Asada K; Tanikawa M; Mori-Uchino M; Tsuruga T; Nagasaka K; Matsumoto Y; Wada-Hiraike O; Osuga Y; Fujii T
BMC Cancer; 2019 May; 19(1):455. PubMed ID: 31092221
[TBL] [Abstract][Full Text] [Related]
13. Downregulation of hsa_circ_0026123 suppresses ovarian cancer cell metastasis and proliferation through the miR‑124‑3p/EZH2 signaling pathway.
Yang X; Wang J; Li H; Sun Y; Tong X
Int J Mol Med; 2021 Feb; 47(2):668-676. PubMed ID: 33416105
[TBL] [Abstract][Full Text] [Related]
14. METTL3 promotes the progression of nasopharyngeal carcinoma through mediating M6A modification of EZH2.
Meng QZ; Cong CH; Li XJ; Zhu F; Zhao X; Chen FW
Eur Rev Med Pharmacol Sci; 2020 Apr; 24(8):4328-4336. PubMed ID: 32373970
[TBL] [Abstract][Full Text] [Related]
15. CARM1-expressing ovarian cancer depends on the histone methyltransferase EZH2 activity.
Karakashev S; Zhu H; Wu S; Yokoyama Y; Bitler BG; Park PH; Lee JH; Kossenkov AV; Gaonkar KS; Yan H; Drapkin R; Conejo-Garcia JR; Speicher DW; Ordog T; Zhang R
Nat Commun; 2018 Feb; 9(1):631. PubMed ID: 29434212
[TBL] [Abstract][Full Text] [Related]
16. Pharmacological inhibition of EZH2 using a covalent inhibitor suppresses human ovarian cancer cell migration and invasion.
Shi L; Zhang Q; Zhu S; Tang Q; Chen X; Lan R; Wang N; Zhu Y
Mol Cell Biochem; 2024 Apr; 479(4):831-841. PubMed ID: 37199893
[TBL] [Abstract][Full Text] [Related]
17. Enhancer of zeste homolog 2 promotes cisplatin resistance by reducing cellular platinum accumulation.
Sun S; Zhao S; Yang Q; Wang W; Cai E; Wen Y; Yu L; Wang Z; Cai J
Cancer Sci; 2018 Jun; 109(6):1853-1864. PubMed ID: 29630768
[TBL] [Abstract][Full Text] [Related]
18. MiRNA-26a Contributes to the Acquisition of Malignant Behaviors of Doctaxel-Resistant Lung Adenocarcinoma Cells through Targeting EZH2.
Chen J; Xu Y; Tao L; Pan Y; Zhang K; Wang R; Chen LB; Chu X
Cell Physiol Biochem; 2017; 41(2):583-597. PubMed ID: 28214878
[TBL] [Abstract][Full Text] [Related]
19. MAPRE3 as an epigenetic target of EZH2 restricts ovarian cancer proliferation in vitro and in vivo.
Zhang Y; Liu F; Zheng J; Jiang K; Ai H; Liu L; Mao D
Exp Cell Res; 2024 Feb; 435(1):113913. PubMed ID: 38199479
[TBL] [Abstract][Full Text] [Related]
20. Long noncoding RNA ATB promotes ovarian cancer tumorigenesis by mediating histone H3 lysine 27 trimethylation through binding to EZH2.
Chen XJ; An N
J Cell Mol Med; 2021 Jan; 25(1):37-46. PubMed ID: 33336896
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
